Zogenix Inc

Zogenix — Investor Presentation (January 2011)

29 slides from Zogenix's investor presentation, Jan 10, 2011

  1. Slide 1: Investor Presentation January 2011

    INVESTOR PRESENTATION January 2011 NASDAQ: ZGNX [ 1 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming

  3. Slide 3: Commercializing and Developing Products for CNS Disorders and Pain

    RAMPING SALES MEDICINE and TECHNOLOGY PHASE 3 DEVELOPMENT ZX002 Commercializing and Developing Products for Treatment of Central Nervous System (CNS) Disorders and Pain Single Use, Needle-Free, Commercial Product $3.5B Market Acute Migraines and Cluster Headaches $13B Market Codeine and Morphine Bas

  4. Slide 4: Established Commercial Infrastructure Positioned for Significant Value Creation

    Established Commercial Infrastructure Positioned for Significant Value Creation SUMAVEL ® DosePro ™ : Differentiated, Marketed Product Phase 3 Ongoing: ZX002 for Chronic Pain DosePro™ Delivery System: Proprietary Technology Experienced Management Team • Sophisticated Manufacturing and Sales Organiza

  5. Slide 5: Sumavel DosePro: Launched Mid-January 2010

    Launched Mid-January 2010 st Single Use, Needle-Free, Commercial Product Marketed for Treating Acute Migraine and Cluster Headaches RAMPING SALES

  6. Slide 6: Million People in the U.S. Suffer Migraines

    30 Million People in the U.S. Suffer Migraines** Symptoms and Nature of Episodes Vary Widely Treatment Depends on Type of Episode 75% of Patients Are Women The 9th Leading Cause of Disability in Women Globally 7th Most Costly Disease to US Employers Disabling Headache Pain, 4-72 Hours in Duration $2

  7. Slide 7: $3.5 Billion Migraine Market

    $3.5 Billion Migraine Market TARGET AUDIENCE: DISSATISFIED ORAL USERS Oral and Nasal Injectable 96% Tablets and Melt Tablets 2% Nasal 2% Injectable* 128 Million Doses CONVENIENCE But… Limited Efficacy for Many Attacks 3.2 Million Doses EFFECTIVE But… 50% of Patients Refuse Needle-based Injection Due

  8. Slide 8: Significant Unmet Needs

    Significant Unmet Needs Patients Want Fast, Complete Pain Relief… … But Most Patients Are Dissatisfied 50% Unsatisfied with Their Current Therapy 75% Said Medication Didn’t Work Fast Enough Majority Said Prescription Oral Medication Not Useful for Every Migraine Attack 30% Fail to Respond to Oral or

  9. Slide 9: SUMAVEL DosePro: A Differentiated Migraine Therapy

    SUMAVEL DosePro: A Differentiated Migraine Therapy COMPLETE EFFECTIVE EASY TO USE FAST Pain Free Pain Relief 98% of Patients Correctly Used SUMAVEL DosePro During Migraine Attacks on Their First Try At Home Pain Relief in as Little as 10 Minutes for Some Patients Sources: SUMAVEL DosePro Prescribing

  10. Slide 10: Highly Effective Treatment for Migraine Pain

    Highly Effective Treatment for Migraine Pain Fastest Time to Maximum Drug Concentration in Blood (Hours) Most Effective Patient Pain Relief at 1 Hour 70% 38-43% 28% 20-30% 12 Minutes 1.6 - 2.5 Hours 1 Hour 1.5 Hours ORAL TABLETS ORAL MELT ORAL TABLETS ORAL MELT Sources: Products’ Prescribing Informa

  11. Slide 11: Rapid, Growing Market Adoption Since January Launch

    Rapid, Growing Market Adoption Since January Launch SUMAVEL DosePro Prescriptions: Over 25,000 TRx To Date Weekly Prescriptions: Rolling 4-Week Average (Through week ending October 22, 2010) $1.9M Net Sales $4.2M Net Sales $5.7M Net Sales Refill Prescriptions New Prescriptions Total Prescriptions Ne

  12. Slide 12: Market Experience To Date: Changing the Way Migraines Are Treated

    Market Experience To Date … We’re Changing the Way Migraines Are Treated New Physicians 32% of Prescribing Physicians Had Not Written a Prescription for Needle- Based Sumatriptan Injections in prior 12 months Sources: Wolters Kluwer Pharma Solutions : Source® LaunchTrac (w/e January 15, – w/e July 3

  13. Slide 13: CONNECT 2010 Most Innovative Product Winner

    SUMAVEL DosePro: CONNECT 2010 Most Innovative Product (MIP) Winner Winner in Life Sciences – Medical Products category Recognizes emerging technologies and cutting-edge products that drive San Diego’s innovation economy DosePro Technology…as easy as 1-2-3

  14. Slide 14: Well-Established Sales and Marketing Organization

    Successfully Executing with Well-Established Sales and Marketing Organization Collaboration With Over 475 Sales Representatives ~ 80 Field Sales Reps, Most Have Neurology and/or Migraine Experience Targeting Neurologists, Headache Clinics and Specialists, Select PCPs 12+ Years Average Experience per

  15. Slide 15: Comprehensive Marketing and Patient Support Programs

    Comprehensive Marketing and Patient Support Programs

  16. Slide 16: Broad Reimbursement Coverage

    Broad Reimbursement Coverage of Reimbursement Claims Submitted Are Approved 79% Source: Wolters Kluwer Pharma Solutions Source® Dynamic Claims (January – November 2010) Tier 3 Reimbursement Strategy Meeting Expectations Broad Coverage with the Largest Commercial Healthcare Plans Range of Physician a

  17. Slide 17: High Quality Partnerships Support Domestic and European Commercialization

    High Quality Partnerships Support Domestic and European Commercialization Manufacturing Distribution and Marketing Europe Manufactured and Released Over 1,000,000 SUMAVEL DosePro Units to Date Contract Manufacturers and Component Suppliers

  18. Slide 18: ZX002: Oral, Single-Entity, Controlled Release Hydrocodone

    ZX002 st Oral, Single-Entity, Controlled Release Hydrocodone for Treating Chronic Pain PHASE 3 DEVELOPMENT

  19. Slide 19: ZX002: Filling A Significant Treatment Gap for Chronic Pain

    ZX002: Filling A Significant Treatment Gap for Chronic Pain NO Hydrocodone Rx Share By Pain Type: ~50% for Chronic Pain Sources: Wolters Kluwer Pharma Solutions, Source® PHAST Retail (12 months ended June 30, 2010), bioStrategies Group (2007) Controlled Release Hydrocodone Single Entity Hydrocodone

  20. Slide 20: /i______ sel

    /i______ sel

  21. Slide 21: ZX002: Late Stage Candidate with Benefits Over Existing Opioids

    ZX002 ZX002: A Late Stage Product Candidate with Numerous Benefits Over Existing Opioids Enables Dose Optimization and Switching from Other Opioids Improves Adherence and Patient Convenience Provides Consistent, Around-the-Clock Relief Eliminates Safety Risks Associated with Acetaminophen Single Ent

  22. Slide 22: DosePro: Proprietary Drug Delivery System

    DosePro: Proprietary Drug Delivery System Validated by FDA Approval of SUMAVEL DosePro 10+ Years Development and Validation US and Foreign IP 61 Issued Patents 31 Patent Applications Pending Proven Ability to Deliver Biologics and Highly Viscous Formulations [ 22

  23. Slide 23: DosePro: Broad Range of Potential Applications

    DosePro: Broad Range of Potential Applications Internal Development Injectable CNS Drug Product Candidates (2 Pre-Clinical) Second Generation Technology (1mL device) Technology Out Licensing Enhance, Differentiate or Extend Injectable Product Lifecycles Attractive Delivery Option for Additional Medi

  24. Slide 24: Large Commercial Opportunities

    12.1 Million TRx per Year 202 Million TRx per Year Large Commercial Opportunities TRx Market 1.26 Million TRx $244 Million 48% of Episodes Upon Morning Wakening (between 4 -9 am) 29% of Sufferers Reported Vomiting as a Symptom of Migraine Attacks 30% of Patients Fail to Respond to Oral or Nasal Trip

  25. Slide 25: Financial Summary

    Financial Summary 9 months ended September 30, 2010 P&L Financial Highlights $ Millions $ Millions Revenue $ 14.6 Operating Expense $ 66.2 Loss From Operations $ 51.6 Other (Income)/Loss $ 19.9 Net Loss $ 71.5 Gross Invoiced Sales $ 16.4 Invested Capital $ 164.0 Cash Balance $ 11.7 Debt Facility $25

  26. Slide 26: 2010 Achievements

    2010 Achievements SUMAVEL DosePro ZX002 Corporate Full U.S. Commercial Launch by Zogenix with co-promote partner Astellas Enhanced Formulary Coverage and Patient Support Phase IV Study Completed Consistent Monthly Rx Growth Since Launch 1 Million Commercial Units Produced Initial EU Approvals by Des

  27. Slide 27: 2011 Goals and Milestones

    2011 Goals and Milestones SUMAVEL DosePro ZX002 DosePro Technology Continue US Sales Growth Phase IV Data Publication Additional EU Approvals New Direct-to-Patient Initiatives Pivotal Study 801 Efficacy Top– Line Results Open Label Study 802 Top-Line Safety Results Initiate Co-Promotion Discussions

  28. Slide 28: Experienced Management Team with a History of Successful Development & Commercialization

    Experienced Management Team with a History of Successful Development & Commercialization Years Experience *Co-Founders Aradigm, Invacare John Turanin* VP/GM, Zogenix Technologies GlaxoSmithKline, Elan, Skin Medica, InterMune Mark Thompson VP, Sales & Managed Markets Nektar, Connetics Edward Smith, P

  29. Slide 29: Established Commercial Infrastructure Positioned for Significant Value Creation

    Established Commercial Infrastructure Positioned for Significant Value Creation SUMAVEL ® DosePro ™ : Differentiated, Marketed Product Phase 3 Ongoing: ZX002 for Chronic Pain DosePro™ Delivery System: Proprietary Technology Experienced Management Team • Sophisticated Manufacturing and Sales Organiza

Zogenix — Investor Presentation (January 2011) on 6ix